Amy Camuso
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies, Click Chemistry and Applications
Most-Cited Works
- → Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor(2005)203 cited
- → Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure(2006)149 cited
- → Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft(2005)85 cited
- → Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels(2006)62 cited
- → Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor(2008)50 cited
- BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo(2005)
- → Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts(2006)30 cited
- → Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model(2005)25 cited
- → Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors(2005)22 cited
- → Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).(2005)18 cited